George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInspiration Hlt Regulatory News (IHC)

Share Price Information for Inspiration Hlt (IHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 28.50
Bid: 28.00
Ask: 29.00
Change: 0.00 (0.00%)
Spread: 1.00 (3.571%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 28.50
IHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

NeuroproteXeon and Linde Distribution Partnership

9 May 2018 15:15

RNS Number : 5532N
Inspiration Healthcare Group PLC
09 May 2018
 

 

Inspiration Healthcare Group plc

("Inspiration Healthcare" or the "Company")

 

European Distribution Partnership signed between

NeuroproteXeon and Linde

 

Inspiration Healthcare Group plc (AIM: IHC), the global medical device company, today announces that NeuroproteXeon Limited ("NeuroproteXeon) in which Inspiration Healthcare holds a has a 8.1 per cent. fully diluted shareholding has completed a distribution agreement with Linde AG (Linde) for XENEXTM (xenon by inhalation) for Post Cardiac Arrest Syndrome ("PCAS") for the European Union plus United Kingdom, Switzerland, Norway and Iceland.

The agreement includes a multi-tiered royalty and 23 million euros in milestone payments. The two key milestone payments are on approval for PCAS from the European Medicines Agency ("EMA") and when Linde reaches cumulative sales of 100 million euros - provided this occurs in the first four years following approval.

Inspiration Healthcare was a founding partner of NeuroproteXeon along with Touchstone Innovations plc (formerly Imperial Innovations plc) and Prof. Mervyn Maze and Prof. Nick Franks. Neil Campbell, Chief Executive Officer of Inspiration Healthcare is a Non-Executive Director of NeuroproteXeon.

 

Neil Campbell, CEO of Inspiration Healthcare Group, said today "We have been involved with xenon delivery for many years and delighted with the agreement signed today with Linde which follows on from the announcement we made in October last year when NeuroproteXeon secured a licence agreement with Mallinckrodt plc. The combination of these world leading companies working with NeuroproteXeon significantly increases the chances for success."

 

Enquiries:

 

Inspiration Healthcare Group plc

Neil Campbell, Chief Executive Officer

Mike Briant, Chief Financial Officer

Tel: 01455 840555

 

Nominated Adviser & Broker

Cenkos Securities plc

Mark Connelly

Tel: 0207 397 8900

 

Cadogan PR

Alex Walters

Tel: 07771 713608

 

 

About Inspiration Healthcare

 

Inspiration Healthcare (AIM: IHC) is a global supplier of medical technology for critical care, operating theatre and other medical applications. The Company provides high quality innovative products to patients and caregivers around the world that help to improve patient outcomes and efficiencies of healthcare organisations with patient focused customer service and technical support.

 

The Company's own brand of critical care solutions span non-invasive respiratory management, thermoregulation and diagnostics, and patient warming for newborns through to adults in intensive care and the operating theatre, whilst the distribution business supplies solutions to support specialised surgical procedures and infusion therapies.

 

Present in over 50 countries worldwide, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving the quality of life of patients, working in close collaboration with key opinion leaders and stakeholders in the clinical and medical community across the globe.

Further information on Inspiration Healthcare can be seen at www.inspiration-healthcare.com

 

About NeuroproteXeon 

NeuroproteXeon, Inc. is a clinical-stage pharmaceutical/device company developing xenon to improve functional capabilities and survival in patients with Post-Cardiac Arrest Syndrome ("PCAS"). The Company has a license agreement with Mallinckrodt LLC (NYSE:MNK) for the sale and distribution of xenon gas for inhalation in North America, Australia and Japan upon approval of the drug in those markets.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGMGGKDLRGRZM
Date   Source Headline
1st Feb 202411:33 amRNSGrant of Covenant Waiver
31st Jan 20247:00 amRNSTrading update
18th Jan 20247:00 amRNSMDSAP certification
15th Jan 20243:04 pmRNSDirector/PDMR Shareholding
4th Jan 20247:00 amRNSStrategic acquisition of Airon Corporation
7th Dec 20237:00 amRNSDirectorate Change
2nd Nov 20237:00 amRNSLaunch of SLE1500 Non-Invasive Ventilator
31st Oct 202310:18 amRNSHolding(s) in Company
17th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSDirector/PDMR Shareholding
12th Oct 20237:00 amRNSShareSoc investor presentation
3rd Oct 20237:00 amRNSHalf-year Report
22nd Sep 20237:00 amRNSInvestor results presentation
31st Aug 20237:00 amRNSTrading update
12th Jul 202310:45 amRNSHolding(s) in Company
10th Jul 20237:00 amRNSChange of Registered Office
27th Jun 202312:20 pmRNSResult of AGM
27th Jun 20237:00 amRNSAGM Statement
22nd Jun 20237:00 amRNSAppointment of Non-Executive Director
13th Jun 20232:00 pmRNSInvestor presentation
12th Jun 20237:00 amRNSCFO appointment
9th Jun 20237:00 amRNSGrant of Options
5th Jun 20235:13 pmRNSHolding(s) in Company
5th Jun 20237:00 amRNSHolding(s) in Company
2nd Jun 20237:00 amRNSNotice of AGM and posting of Annual Report
1st Jun 20233:27 pmRNSAIM Rule 17 Schedule Two (g) Update
1st Jun 20238:55 amRNSHolding(s) in Company
24th May 20237:00 amRNSAppointment of Nominated Adviser and Broker
17th May 20237:00 amRNSMello investor conference
4th May 20237:00 amRNSInvestor Day
3rd May 20237:00 amRNSFinal Results
6th Apr 20235:53 pmRNSGrant of Options
3rd Apr 20235:53 pmRNSGrant of Options
31st Mar 20236:27 pmRNSExercise of Options & Issue of Equity
23rd Mar 20237:00 amRNSLaunch of range extension of neonatal ventilators
1st Mar 20237:00 amRNSChange of Website
17th Feb 20232:05 pmRNSTR1 Notification
16th Feb 20237:00 amRNSTrading Update
9th Dec 20222:27 pmRNSTR1 Notification
8th Dec 20221:10 pmRNSTR1 Notification
5th Dec 20227:00 amRNSBoard Changes
30th Nov 202210:28 amRNSDirector / PDMR Dealing
28th Nov 20222:05 pmRNSSecond Price Monitoring Extn
28th Nov 20222:00 pmRNSPrice Monitoring Extension
28th Nov 20229:05 amRNSSecond Price Monitoring Extn
28th Nov 20229:00 amRNSPrice Monitoring Extension
28th Nov 20227:00 amRNSUpdate on Trading

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.